Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl Regillo

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Journal of Vitreoretinal Diseases|April 3, 2023
Treatment of Eyes With Diabetic Macular Edema That Had a Suboptimal Response to Antivascular Endothelial Growth Factor Therapy: 2-mg Intravitreal Triamcinolone Acetonide vs 0.7-mg Dexamethasone ImplantBrandon Kuley, Philip P Storey, Maitri Pancholy, et al.
Journal of Vitreoretinal Diseases|April 3, 2023
Clinical Characteristics and Management Outcomes of Rhegmatogenous Retinal Detachments Due to Retinal DialysisRaziyeh Mahmoudzadeh, Denis Huang, Mirataollah Salabati, et al.
Eye (London, England)|December 18, 2025
TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degenerationCarl Regillo, Peter K Kaiser, Peter J Kertes, et al.
Seminars in Ophthalmology|April 29, 2020
Ocular Hypertension Following Intravitreal Injection of 0.7mg Dexamethasone Implant versus 2mg TriamcinoloneBrandon Kuley, Philip P Storey, Maitri Pancholy, et al.
Retina (Philadelphia, Pa.)|October 21, 2022
REFRACTIVE ERROR CHANGE DURING TREATMENT OF DIABETIC MACULAR EDEMA: A Post Hoc Analysis of the Diabetic Retinopathy Clinical Research Protocol T TrialMirataollah Salabati, Raziyeh Mahmoudzadeh, Matthew R Starr, et al.
Ophthalmology. Retina|June 4, 2025
TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular DegenerationCarl Regillo, Peter K Kaiser, Peter J Kertes, et al.
BMJ Open Ophthalmology|April 29, 2021
Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): Development of a patient-reported measure to assess treatment burden of repeat intravitreal injectionsCynthia K McClard, Rui Wang, Victoria Windham, et al.
Eye (London, England)|October 11, 2025
Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatmentArshad M Khanani, Sophie J Bakri, Carl Regillo, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|August 28, 2020
Ocular hypertension following 40 mg sub-Tenon triamcinolone versus 0.7 mg dexamethasone implant versus 2 mg intravitreal triamcinoloneBrandon Kuley, Philip P Storey, Maitri Pancholy, et al.
Ophthalmology. Retina|May 29, 2024
Screen Failures in Clinical Trials in RetinaNasiq Hasan, Kunaal Mehrotra, Carl J Danzig, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Journal of Vitreoretinal Diseases|April 3, 2023
Treatment of Eyes With Diabetic Macular Edema That Had a Suboptimal Response to Antivascular Endothelial Growth Factor Therapy: 2-mg Intravitreal Triamcinolone Acetonide vs 0.7-mg Dexamethasone ImplantBrandon Kuley, Philip P Storey, Maitri Pancholy, et al.
Journal of Vitreoretinal Diseases|April 3, 2023
Clinical Characteristics and Management Outcomes of Rhegmatogenous Retinal Detachments Due to Retinal DialysisRaziyeh Mahmoudzadeh, Denis Huang, Mirataollah Salabati, et al.
Eye (London, England)|December 18, 2025
TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degenerationCarl Regillo, Peter K Kaiser, Peter J Kertes, et al.
Seminars in Ophthalmology|April 29, 2020
Ocular Hypertension Following Intravitreal Injection of 0.7mg Dexamethasone Implant versus 2mg TriamcinoloneBrandon Kuley, Philip P Storey, Maitri Pancholy, et al.
Retina (Philadelphia, Pa.)|October 21, 2022
REFRACTIVE ERROR CHANGE DURING TREATMENT OF DIABETIC MACULAR EDEMA: A Post Hoc Analysis of the Diabetic Retinopathy Clinical Research Protocol T TrialMirataollah Salabati, Raziyeh Mahmoudzadeh, Matthew R Starr, et al.
Ophthalmology. Retina|June 4, 2025
TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular DegenerationCarl Regillo, Peter K Kaiser, Peter J Kertes, et al.
BMJ Open Ophthalmology|April 29, 2021
Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): Development of a patient-reported measure to assess treatment burden of repeat intravitreal injectionsCynthia K McClard, Rui Wang, Victoria Windham, et al.
Eye (London, England)|October 11, 2025
Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatmentArshad M Khanani, Sophie J Bakri, Carl Regillo, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|August 28, 2020
Ocular hypertension following 40 mg sub-Tenon triamcinolone versus 0.7 mg dexamethasone implant versus 2 mg intravitreal triamcinoloneBrandon Kuley, Philip P Storey, Maitri Pancholy, et al.
Ophthalmology. Retina|May 29, 2024
Screen Failures in Clinical Trials in RetinaNasiq Hasan, Kunaal Mehrotra, Carl J Danzig, et al.
Pageof 4